Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Adefovir+Lamivudine vs Entecavir+Adefovir in Lamivudine-Resistant CHB
NCT00986778Phase 4Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of patients with HBV DNA < 50 IU/mL at Week 48. Planned start Dec 2009; status: withdrawn.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00986778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986778.